Richard Scolyer Dies at 59 After Defying 1-Year Glioblastoma Survival Odds
Updated
Updated · The New York Times · Jun 26
Richard Scolyer Dies at 59 After Defying 1-Year Glioblastoma Survival Odds
3 articles · Updated · The New York Times · Jun 26
Summary
June 7 marked the death in Sydney of Richard Scolyer, the Australian pathologist whose melanoma research reshaped diagnosis and understanding of the country’s most prevalent cancer.
Diagnosed with advanced glioblastoma in 2023, Scolyer lived well beyond the roughly one-year median survival for the aggressive brain cancer while undergoing experimental immunotherapy.
Three years into that fight, he publicly documented his treatment in social media posts, televised interviews and his 2024 autobiography “Brainstorm,” effectively becoming a subject of his own research story.
Anthony Albanese announced Scolyer’s death and said he would receive a state funeral; the prime minister had already backed his legacy with A$5.9 million in 2025 for the Richard Scolyer Chair in Brain Research.
A doctor used his own research to fight brain cancer. What can his case teach us about treating other incurable diseases?
With personalized cancer cures costing hundreds of thousands, how can we ensure they don't just benefit the wealthy?
Breaking Barriers in Brain Cancer: Dr. Richard Scolyer, Experimental Immunotherapy, and the GIANT Trial for Glioblastoma
Overview
Dr. Richard Scolyer, a world-renowned Australian pathologist, passed away in June 2026 after nearly three years battling glioblastoma. His death sparked global recognition and sorrow, highlighting his groundbreaking work in melanoma research and his courageous personal fight against brain cancer. Even before his passing, his efforts drew significant public and governmental attention, leading to major funding for brain research in his name. Dr. Scolyer’s legacy is marked by his profound contributions to medical science and the inspiration he provided through his dedication, advocacy, and willingness to pioneer new treatments, shaping the future of cancer research.